By Michael Erman and Manas Mishra (Reuters) -Advisers to the U.S. Food and Drug Administration on Tuesday will vote on whether to recommend authorizing Novavax Inc’s COVID-19 vaccine, which the drugmaker hopes can become the shot of choice among some American vaccine skeptics. The shot being considered by the FDA panel of outside experts is a more traditional type of vaccine employing technology that has been used for decades to combat diseases including Hepatitis B and influenza. Maryland-based Novavax is hoping to gain a foothold within the roughly 27 million U.S. adults who are yet to be va…